IL-2 gene polymorphisms affect tacrolimus response in myasthenia gravis.
Eur J Clin Pharmacol
; 75(6): 795-800, 2019 Jun.
Article
em En
| MEDLINE
| ID: mdl-30729267
ABSTRACT
PURPOSE:
The IL-2 gene polymorphisms have been reported to be associated with the development of autoimmune disease. However, there are no published studies examining the influence of the IL-2 gene polymorphisms on the response of myasthenia gravis (MG) patients to tacrolimus (Tac). The goal of this study was to investigate the relationship between the polymorphisms of IL-2 and Tac response in MG patients.METHODS:
Ninety-two MG patients treated with Tac were studied, including 57 Tac-effective patients and 35 Tac-ineffective patients. Then, we selected four single-nucleotide polymorphisms (SNPs rs2069776, rs2069772, rs2069762, rs2069763) in the IL-2 gene. Next, we analyzed the distribution of genotypes, allelic frequencies of SNPs, and haplotype frequencies among polymorphisms in the two groups of patients.RESULTS:
The distribution of the allelic frequency of the rs2069762 variant differed between the Tac-effective and Tac-ineffective patients (P = 0.02). Genotypes G/T and G/G of rs2069762 were differently distributed between the two groups when the wild genotype T/T was assigned as a reference (P < 0.001 for G/T; P = 0.003 for G/G). Patients with the TAGG haplotype tended to be Tac-ineffective (P < 0.001, OR 0.15, 95% CI 0.05-0.43).CONCLUSION:
Myasthenia gravis patients with the rs2069762 variant, rs2069762 G/T and G/G genotype, and TAGG haplotype for IL-2 tended to respond poorly to Tac treatment.Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Interleucina-2
/
Tacrolimo
/
Imunossupressores
/
Miastenia Gravis
Limite:
Adult
/
Female
/
Humans
/
Male
Idioma:
En
Revista:
Eur J Clin Pharmacol
Ano de publicação:
2019
Tipo de documento:
Article